Finance News – Sarepta
What is your interest today?
- ABC News Business
- BBC Business
- Business Insider Markets
- CBC Business
- City A.M.
- CNBC Business
- CoinDesk
- Cointelegraph
- Crypto News
- CryptoSlate
- Decrypt
- Economic Times Markets
- Euronews Business
- Financial Post Top Stories
- Financial Times
- Finextra Crypto
- Finextra Market
- Finextra Wealth
- Globe and Mail Investing
- Investing.com Global Markets
- Investing.com Global Mkts
- Investopedia
- Kiplinger
- MarketWatch MarketPulse
- MarketWatch Top Stories
- Quartz
- Sky News Money
- Sydney Morning Herald Biz
- Sydney Morning Herald Business
- TechCrunch Fintech
- The Block
- The Guardian – Business
- WSJ Markets News
Top Stock Movers Now: Verizon, Cleveland-Cliffs, Newmont, Sarepta, and More
Several major companies, including Verizon and Newmont, experienced notable changes in their market values today, reflecting shifts in investor sentiment and potential impacts on q...
Read Full Article →Sarepta Stock Keeps Sliding as Company Rejects FDA Call to Withdraw Drug
The company’s shares declined further after it declined the regulatory agency’s request to remove its medication from the market, raising concerns about future revenue and investor...
Read Full Article →Sarepta stock extends decline as company declines FDA call to withdraw drug
Sarepta Therapeutics' shares continued to fall following the company's decision to reject the FDA’s request to remove a medication linked to multiple fatalities from the market.
Read Full Article →Sarepta drops another 5% to $13.37 after downgrades, FDA probe
The company’s shares declined significantly following reduced analyst ratings and an ongoing investigation by regulatory authorities, impacting investor confidence and market valua...
Read Full Article →Sarepta says will continue to ship Elevidys to ambulant population
Maintaining distribution of their treatment to patients able to walk could potentially support Sarepta's revenue growth and market presence in the neuromuscular disorder sector.
Read Full Article →Sarepta shares plunge 40% as future of its gene therapy appears at risk
Sarepta experienced a substantial decline in stock value following reports of a third fatality associated with its gene therapy treatments, raising concerns about the company’s fut...
Read Full Article →Here's Why Sarepta Stock Is Jumping Thursday
Shares of Sarepta experienced a notable increase on Thursday, reflecting investor optimism driven by recent developments and expectations about the company’s future financial perfo...
Read Full Article →